Related Experiment Video

Updated: Apr 24, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

2.4K

Beyond BRAF: where next for melanoma therapy?

I V Fedorenko1, G T Gibney2, V K Sondak2

  • 1The Department of Molecular Oncology, The Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.

British Journal of Cancer
|September 3, 2014
PubMed

Insights

Melanoma treatment advances, including BRAF inhibitors, offer hope but face resistance. Future strategies focus on combination therapies and personalized medicine for BRAF-mutant, NRAS-mutant, and wild-type melanoma.

Area of Science:

  • Oncology
  • Dermatology
  • Precision Medicine

Background:

  • Melanoma treatment has seen significant progress with targeted therapies, particularly BRAF inhibitors.
  • BRAF and MEK inhibitor combinations have improved outcomes for BRAF-mutant melanoma patients.
  • However, treatment resistance remains a major challenge, limiting long-term efficacy.

Purpose of the Study:

  • To review current and future combination strategies for BRAF-mutant melanoma.
  • To explore emerging therapeutic options for NRAS-mutant and BRAF/NRAS-wild-type melanoma.
  • To highlight advancements in personalized therapy for melanoma.

Main Methods:

  • Review of recent scientific literature on melanoma targeted therapies.
  • Analysis of clinical trial data for combination strategies.
  • Discussion of emerging therapeutic targets and personalized medicine approaches.

Main Results:

  • BRAF/MEK inhibitor combinations show promise but are not universally effective.
  • Resistance mechanisms necessitate novel therapeutic combinations.
  • Personalized medicine approaches are crucial for optimizing treatment outcomes.

Conclusions:

  • Combination therapies are essential for overcoming treatment resistance in melanoma.
  • Targeting NRAS-mutant and wild-type melanoma requires distinct strategies.
  • Personalized treatment strategies will continue to advance melanoma care.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

18.0K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

8.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K